The purpose of this study has three aspects ： to see the clinical effect of adjunctive treatment of valproic acid to haloperidol in treatment-resistant schizophrenia, to see whether valproic acid has any influence on the plasma concentration of haloperidol, and to see whether there is any correlation between clinical change and the changes of the plasma concentration of these two drugs. Valproic acid(mean = 880mg/day) is administrated to 25 treatment-resistant schizophrenic patients, and among them 8 patients dropped out because of the side effect. There was significant improvement in the negative(p = 0.003) and general psychopathology scales(p = 0. 009) of PANSS. The mean concentration of valproic acid has decreased on the fourth week(p = 0.002), whereas the mean plasma concentration of haloperidol has increased on the second and fourth week of the study(p = 0.001). However, we could not find any correlation of between the plasma concentration of valproic acid and haloperidol. As conclusion, the adjunctive treatment of valproic acid to haloperidol in the treatment-resistant schizophrenia has improved in negative schizophrenic symptoms rather than in the positive symptoms. This suggests the usefulness of adjunctive treatment in terms of improving the overall quality of the life of the treatment- resistant schizophrenic patients
서 론
연구대상 및 방법
결 과
고 찰
요 약
참고문헌